pre-IPO PHARMA

COMPANY OVERVIEW

Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology. Mitochon’s lead programs, MP101 and MP-201, specifically target the mitochondria to provide broad neural protection. These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival – similar to the positive effects seen with fasting and exercise.


LOCATION

  • Blue Bell, PA, USA

  • THERAPEUTIC AREAS

  • Neurological DIsorders

  • WEBSITE

    https://www.mitochonpharma.com/


    CAREER WEBSITE

    https://www.mitochonpharma.com/careers/


    SOCIAL MEDIA


    INVESTORS

    ben-franklin-technology-partners yt-angels


    PRESS RELEASES


    Sep 28, 2021

    Mitochon Pharmaceuticals and University of Kentucky Awarded MTEC Grant for MP-201 in Traumatic Brain Injury


    Jun 23, 2020

    University of Kentucky, Children’s Hospital of Philadelphia and Mitochon Pharmaceuticals Awarded NIH Grant for Traumatic Brain Injury Studies


    Jun 23, 2020

    University of Kentucky, Children’s Hospital of Philadelphia and Mitochon Pharmaceuticals Awarded NIH Grant for Traumatic Brain Injury Studies


    Mar 5, 2019

    Mitochon Pharmaceuticals Awarded Orphan Drug Designation


    Nov 8, 2017

    Mitochon Pharmaceuticals Announces First Patent Allowance for Mitochondrial Targeted Therapies for Neurodegeneration


    For More Press Releases


    Google Analytics Alternative